Literature DB >> 29038252

A Bacteriophage Capsid Protein Is an Inhibitor of a Conserved Transcription Terminator of Various Bacterial Pathogens.

Gairika Ghosh1,2, Jayavardhana Reddy1, Susmit Sambhare1, Ranjan Sen3.   

Abstract

Rho is a hexameric molecular motor that functions as a conserved transcription terminator in the majority of bacterial species and is a potential drug target. Psu is a bacteriophage P4 capsid protein that inhibits Escherichia coli Rho by obstructing its ATPase and translocase activities. In this study, we explored the anti-Rho activity of Psu for Rho proteins from different pathogens. Sequence alignment and homology modeling of Rho proteins from pathogenic bacteria revealed the conserved nature of the Psu-interacting regions in all these proteins. We chose Rho proteins from various pathogens, including Mycobacterium smegmatis, Mycobacterium bovis, Mycobacterium tuberculosis, Xanthomonas campestris, Xanthomonas oryzae, Corynebacterium glutamicum, Vibrio cholerae, Salmonella enterica, and Pseudomonas syringae The purified recombinant Rho proteins of these organisms showed variable rates of ATP hydrolysis on poly(rC) as the substrate and were capable of releasing RNA from the E. coli transcription elongation complexes. Psu was capable of inhibiting these two functions of all these Rho proteins. In vivo pulldown assays revealed direct binding of Psu with many of these Rho proteins. In vivo expression of psu induced killing of M. smegmatis, M. bovis, X. campestris, and E. coli expressing S. enterica Rho indicating Psu-induced inhibition of Rho proteins of these strains under physiological conditions. We propose that the "universal" inhibitory function of the Psu protein against the Rho proteins from both Gram-negative and Gram-positive bacteria could be useful for designing peptides with antimicrobial functions and that these peptides could contribute to synergistic antibiotic treatment of the pathogens by compromising the Rho functions.IMPORTANCE Bacteriophage-derived protein factors modulating different bacterial processes could be converted into unique antimicrobial agents. Bacteriophage P4 capsid protein Psu is an inhibitor of the E. coli transcription terminator Rho. Here we show that apart from antagonizing E. coli Rho, Psu is able to inhibit Rho proteins from various phylogenetically unrelated Gram-negative and Gram-positive pathogens. Upon binding to these Rho proteins, Psu inhibited them by affecting their ATPase and RNA release functions. The expression of Psu in vivo kills various pathogens, such as Mycobacterium and Xanthomonas species. Hence, Psu could be useful for identifying peptide sequences with anti-Rho activities and might constitute part of synergistic antibiotic treatment against pathogens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Psu; RNA polymerase; RNA polymerases; Rho; bacteriophage; pathogen; transcription termination

Mesh:

Substances:

Year:  2017        PMID: 29038252      PMCID: PMC5717163          DOI: 10.1128/JB.00380-17

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  36 in total

1.  Transcription termination factor rho prefers catalytically active elongation complexes for releasing RNA.

Authors:  Dipak Dutta; Jisha Chalissery; Ranjan Sen
Journal:  J Biol Chem       Date:  2008-05-15       Impact factor: 5.157

Review 2.  Keeping up to speed with the transcription termination factor Rho motor.

Authors:  Marc Boudvillain; Marcello Nollmann; Emmanuel Margeat
Journal:  Transcription       Date:  2010 Sep-Oct

3.  Interaction with the nascent RNA is a prerequisite for the recruitment of Rho to the transcription elongation complex in vitro.

Authors:  B Sudha Kalyani; Ghazala Muteeb; M Zuhaib Qayyum; Ranjan Sen
Journal:  J Mol Biol       Date:  2011-09-06       Impact factor: 5.469

4.  Ligand-induced and small-molecule control of substrate loading in a hexameric helicase.

Authors:  Michael R Lawson; Kevin Dyer; James M Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

5.  Bicyclomycin, a new antibiotic. 3. In vitro and in vivo antimicrobial activity.

Authors:  M Nishida; Y Mine; T Matsubara; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1972-10       Impact factor: 2.649

6.  A bacterial transcription terminator with inefficient molecular motor action but with a robust transcription termination function.

Authors:  Nisha C Kalarickal; Amitabh Ranjan; B Sudha Kalyani; Megha Wal; Ranjan Sen
Journal:  J Mol Biol       Date:  2009-12-21       Impact factor: 5.469

Review 7.  Rho-dependent transcription termination: more questions than answers.

Authors:  Sharmistha Banerjee; Jisha Chalissery; Irfan Bandey; Ranjan Sen
Journal:  J Microbiol       Date:  2006-02       Impact factor: 3.422

8.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

9.  Transcription termination defective mutants of Rho: role of different functions of Rho in releasing RNA from the elongation complex.

Authors:  Jisha Chalissery; Sharmistha Banerjee; Irfan Bandey; Ranjan Sen
Journal:  J Mol Biol       Date:  2007-06-09       Impact factor: 5.469

10.  The moonlighting function of bacteriophage P4 capsid protein, Psu, as a transcription antiterminator.

Authors:  Amitabh Ranjan; Ramanuj Banerjee; Bibhusita Pani; Udayditya Sen; Ranjan Sen
Journal:  Bacteriophage       Date:  2013-04-01
View more
  5 in total

1.  Exploiting phage strategies to modulate bacterial transcription.

Authors:  Markus C Wahl; Ranjan Sen
Journal:  Transcription       Date:  2019-10-30

2.  Mycobacteriophage CRB2 defines a new subcluster in mycobacteriophage classification.

Authors:  Cristian Alejandro Suarez; Jorgelina Judith Franceschelli; Héctor Ricardo Morbidoni
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

3.  Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review.

Authors:  Taher Azimi; Mehrdad Mosadegh; Mohammad Javad Nasiri; Sahar Sabour; Samira Karimaei; Ahmad Nasser
Journal:  Infect Drug Resist       Date:  2019-09-17       Impact factor: 4.003

4.  Mycolicibacterium smegmatis, Basonym Mycobacterium smegmatis, Expresses Morphological Phenotypes Much More Similar to Escherichia coli Than Mycobacterium tuberculosis in Quantitative Structome Analysis and CryoTEM Examination.

Authors:  Hiroyuki Yamada; Masashi Yamaguchi; Yuriko Igarashi; Kinuyo Chikamatsu; Akio Aono; Yoshiro Murase; Yuta Morishige; Akiko Takaki; Hiroji Chibana; Satoshi Mitarai
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

5.  Prophage Gene Rv2650c Enhances Intracellular Survival of Mycobacterium smegmatis.

Authors:  Xiangyu Fan; Zichen Liu; Zhibin Wan; Hanlu Zou; Mengzhi Ji; Kaili Sun; Rongfeng Gao; Zhongfang Li; Wu Li
Journal:  Front Microbiol       Date:  2022-01-17       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.